title: Anti-interleukin-6 antibodies attenuate inflammation in a rat meningitis model.
abstract: OBJECTIVE
  Interleukin-6 (IL-6) is elevated in the cerebrospinal fluid (CSF) of humans and animals with bacterial meningitis. This study's hypothesis was that anti-IL-6 antibodies will attenuate meningeal inflammation in a rat model of bacterial meningitis.
  
  
  METHODS
  14 male Sprague-Dawley rats were inoculated intracisternally (IC) with 0.1 mL of heat-killed pneumococci. At one hour post-inoculation, the rats received intraperitoneal doses of either 1.0 mL phosphate-buffered saline (PBS treatment group, n = 7) or 70 microg anti-IL-6 antibodies in 1.0 mL PBS (anti-IL-6 antibody treatment group, n = 7). Nine rats (normal group, n = 9) had no inoculation, and four rats (surgical sham group, n = 4) had IC inoculations of saline. At six hours post-inoculation, all the animals had CSF removed via IC tap. The CSF protein and white blood cell (WBC) count measures were compared using a t-test.
  
  
  RESULTS
  Mean CSF WBC for the anti-IL-6 treatment group was 2,458/microL, versus the PBS controls' mean of 9,697/microL (p = 0.007). Mean CSF protein for the anti-IL-6 group was 180 mg/dL, versus 296 mg/dL for the controls (p = 0.032). The surgical sham and normal animals had normal CSF WBC and protein values.
  
  
  CONCLUSIONS
  In this rat meningitis model, systemic treatment with anti-IL-6 antibodies after the induction of meningitis suppressed both CSF WBC count and CSF protein level, two important indices of meningeal inflammation.
authors.affiliation: Section of Emergency Medicine, Department of Pediatrics, Brown University School of Medicine, Providence, RI, USA.
authors.forename: D
authors.initials: D
authors.lastname: Marby
authors.forename: G R
authors.initials: GR
authors.lastname: Lockhart
authors.forename: R
authors.initials: R
authors.lastname: Raymond
authors.forename: J G
authors.initials: JG
authors.lastname: Linakis
mesh_terms: D000818:Animals; D000906:Antibodies / Q000008:administration & dosage / Q000134:cerebrospinal fluid* / Q000276:immunology*; D002556:Cerebrospinal Fluid Proteins / Q000378:metabolism; D004195:Disease Models, Animal; D007267:Injections; D015850:Interleukin-6 / Q000134:cerebrospinal fluid* / Q000276:immunology*; D007958:Leukocyte Count; D007964:Leukocytosis / Q000097:blood / Q000134:cerebrospinal fluid / Q000276:immunology; D008297:Male; D016920:Meningitis, Bacterial / Q000097:blood / Q000134:cerebrospinal fluid* / Q000276:immunology*; D011008:Pneumococcal Infections / Q000097:blood / Q000134:cerebrospinal fluid* / Q000276:immunology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013346:Subarachnoid Space; D016896:Treatment Outcome
chemical_list: D000906:Antibodies; D002556:Cerebrospinal Fluid Proteins; D015850:Interleukin-6